Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis

Gut

Volumn 38, Issue 3, 1996, Pages 439-446

  Setchell, K D R ^a   Rodrigues, C M P ^a   Podda, M ^b   Crosignani, A ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Bile acids; Metabolism; Primary biliary cirrhosis; Tauroursodeoxycholic acid; Ursodeoxycholic acid

Indexed keywords

CERULETIDE; TAUROURSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; METABOLISM; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

EID: 0029863605     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.3.439     Document Type: Article

References (55)

1. Poupon P, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; i: 834-6.
2. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74.
3. Stiehl A, Raedsch R, Theilmann L, Galle P. The effect of ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 1989; 96: 664A.
4. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Ursodeoxycholic acid, taurine or a combination of the two for chronic hepatitis. Gastroenterology 1990; 98: 1044-50.
5. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-3.
6. Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A, Curcio L, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990; 117: 482-9.
7. Poupon RE, Balkau B, Eschwege E, Poupon R and the UDCA-PBC study group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
8. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989; 10: 414-9.
9. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-5.
10. Poupon RE, Poupon R, Balkau B and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Eng J Med 1994; 330: 1342-7.
11. Armstrong MJ, Carey MC. The hydrophobic/hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 1982; 23: 70-80.
12. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986; 19: 57-68.
13. Hofmann AF. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses. In: Paumgartner G, Stiehl A, Barbara L, Roda E, eds. Strategies for the treatment of hepatobiliary diseases. Dordrecht, The Netherlands: Kluwer Academic, 1990; 13-34.
14. Heuman DM. Quantitative estimation of hydrophobic-hydrophilic balance of mixed bile salts solutions. J Lipid Res 1989; 30: 719-30.
15. Krol T, Kitamura T, Miyai K, Hardison W. Tauroursodeoxycholate (TUDC) reduces ductular proliferation and portal inflammation in bile duct-ligated hamsters. Hepatology 1983; 3: 881
16. Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985; 248: 407-17.
17. Nakai T, Katagiri K, Hoshino N, Hayakawa T, Ohiwa T. Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine-treated rat liver. Biochem J 1992; 288: 613-7.
18. Tsukahara K, Kanai S, Ohta M, Kitani K. Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 1993; 13: 262-9.
19. Heuman DM, Dajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106: 1333-41.
20. Crosignani A, Podda M, Battezzati PM, Bertolini H, Zuin M, Watson D, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000-7.
21. Crosignani A, Battezzati PM, Camisasca M, Bertolini E, Govini G, Zuin M, et al. Tauroursodeoxycholic acid for the treatment of primary biliary cirrhosis: a dose-response study. Hepatology 1993; 18: 176A.
22. Vonk RJ, Kneepkens CMF, Havina R, Kuipers F, Bijleveld CMA. Enterohepatic circulation in man: a single method for the determination of duodenal bile acids. J Lipid Res 1986; 27: 901-4.
23. Setchell KDR, Worthington J. A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phrase octadecylsilane bonded silica cartridges. Clin Chim Acta 1982; 125: 135-44.
24. Almé B, Bremmelgaard A, Sjövall J, Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. J Lipid Res 1977; 18: 339-62.
25. Hirano Y, Miyazaki H, Higashidate S, Nakayama F. Analysis of 3-sulfated and non sulfated bile acids by one-step hydrolysis and high performance liquid chromatography. J Lipid Res 1987; 28: 1524-9.
26. Nair PP, Garcia CC. A modified gas-liquid chromatographic procedure for the rapid determination of bile acids in biological fluids. Anal Biochem 1969; 29: 164-6.
27. Lawson AM, Setchell KDR. Mass spectrometry of bile-acids. In: Setchell KDR, Kritchevsky D, Nair PP, eds. The bile acids, vol 4. Methods and applications. New York: Plenum Press, 1988: 167-267.
28. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 1987; 28: 589-95.
29. Stefaniwsky AB, Tint GS, Speck J, Shefer S, Salen G. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology 1985; 89: 1000-4.
30. Holubec H, Earnest D, Jolley C, Bhattacharyya A, Allen C, Bissonnette M, et al. Ursodeoxycholic acid protects against experimental colon cancer. Gastroenterology 1994; 106: 393A.
31. Erlinger S. Hypercholeretic bile acids: a clue to mechanism? Hepatology 1990; 11: 888-90.
32. Leuschner U, Güldütuna S, Imhof M, Hubnea K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and later stage of primary biliary cirrhosis. J Hepatol 1994; 21: 624-33.
33. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989; 34: 59-65S.
34. Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KDR. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 1991; 13: 1076-83.
35. Dumont M, Erlinger S, Uchman S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in rat: possible role of bicarbonate transport. Gastroenterology 1980; 79: 82-9.
36. + exchange inhibitors. Am J Physiol 1988; 254: G232-41.
37. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis: a review. Dig Dis Sci 1982; 27: 833-56.
38. Walker S, Rudolf G, Raedsch R, Stiehl A. Intestinal absorption of UDCA in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992; 102: 810-5.
39. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14: 920-6.
40. Hofmann AF. Pharmacology of chenodeoxycholic acid and ursodeoxycholic acid in man. In: Paumgartner G, Stiehl A and Gerok W, eds. Bile acids and cholesterol in health and disease. Dordrecht, The Netherlands: Kluwer Academic, 1983: 301-36.
41. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. Tauroursodeoxycholate increases rat liver ursodeoxycholate and limits lithocholate formation better than ursodeoxycholate. Gastroenterology 1995; 109: 564-72.
42. Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990; 12: 322-34.
43. Ferri F, Bernocchi P, Fedeli S. Tauroursodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid. Clin Ther 1993; 143: 321-6.
44. Cetta F, Lombardo F, Cappelli A, Giubbolini M, Bichi A, Baldi C. A double blind trial with bile acid therapy in the prophylaxis of cholesterol stone recurrence in the cystic remnant after laparoscopic cholecystectomy. Preliminary report. Gastroenterology 1994; 106: 335A.
45. Fedorowski T, Salen G, Colallilo A, Tint GS, Mosbach EH, Hall JC. Metabolism of ursodeoxycholic acid in man. Gastroenterology 1977; 73: 1131-7.
46. Fromm H, Carlson GL, Hofmann AF, Farivar S, Amin P. Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids. Am J Physiol 1980; 239: G161-6.
47. Fedorowski T, Salen G, Tint GS, Mosbach H. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology 1979; 77: 1068-73.
48. Beuers U, Spengler U, Zwiebel MF, Pauletzki J, Fischer S, Gustav P. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and chronic cholestatic liver disease. Hepatology 1992; 15: 603-8.
49. Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatalogy 1993; 17: 1028-32.
50. Heuman DM, Vlahcevic ZR, Bailey ML, Hylemon PB. Regulation of bile acid synthesis. II. Effect of bile acid feeding on enzymes regulating hepatic cholesterol and bile acid synthesis in the rat. Hepatology 1988; 8: 892-7.
51. Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12: 1206-8.
52. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98: 424-8.
53. Van Berge-Henegouwen GP, Hofmann AF. Systemic spill-over of bile acids. Eur J Clin Invest 1983; 13: 433-7.
54. Murphy GM. Serum bile acids. In: Setchell KDR, Kritchevsky D, Nair PP, eds. The bile acids, vol 4: Methods and Applications. New York: Plenum Press, 1988: 379-403.
55. Javitt NB. Ursodeoxycholic acid therapy: the baby and the bathwater. Hosp Pract 1992; 27: 126.